Research Papers:

A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib

Wayne D. Blosser, Jack A. Dempsey, Ann M. McNulty, Xi Rao, Philip J. Ebert, Caitlin D. Lowery, Philip W. Iversen, Yue Wang Webster, Gregory P. Donoho, Xueqian Gong, Farhana F. Merzoug, Sean Buchanan, Karsten Boehnke, Chunping Yu, Xin Tian You, Richard P. Beckmann, Wenjuan Wu, Samuel C. McNeely, Aimee Bence Lin and Ricardo Martinez _

PDF  |  Full Text  |  Supplementary Files  |  How to cite

Oncotarget. 2020; 11:216-236. https://doi.org/10.18632/oncotarget.27400

Metrics: PDF 2644 views  |   Full Text 4005 views  |   ?  


Wayne D. Blosser1, Jack A. Dempsey1, Ann M. McNulty1, Xi Rao1, Philip J. Ebert1, Caitlin D. Lowery1, Philip W. Iversen1, Yue Wang Webster1, Gregory P. Donoho1, Xueqian Gong1, Farhana F. Merzoug1, Sean Buchanan1, Karsten Boehnke2, Chunping Yu3, Xin Tian You3, Richard P. Beckmann1, Wenjuan Wu1, Samuel C. McNeely1, Aimee Bence Lin1 and Ricardo Martinez1

1 Eli Lilly and Company, Indianapolis, IN, USA

2 Eli Lilly and Company, New York, NY, USA

3 Eli Lilly and Company, Shanghai, China

Correspondence to:

Ricardo Martinez,email: [email protected]

Keywords: CHK1; prexasertib; replication stress; replication fork; innate immunity

Received: September 19, 2019     Accepted: December 02, 2019     Published: January 21, 2020


The combined influence of oncogenic drivers, genomic instability, and/or DNA damage repair deficiencies increases replication stress in cancer. Cells with high replication stress rely on the upregulation of checkpoints like those governed by CHK1 for survival. Previous studies of the CHK1 inhibitor prexasertib demonstrated activity across multiple cancer types. Therefore, we sought to (1) identify markers of prexasertib sensitivity and (2) define the molecular mechanism(s) of intrinsic and acquired resistance using preclinical models representing multiple tumor types. Our findings indicate that while cyclin E dysregulation is a driving mechanism of prexasertib response, biomarkers associated with this aberration lack sufficient predictive power to render them clinically actionable for patient selection. Transcriptome analysis of a pan-cancer cell line panel and in vivo models revealed an association between expression of E2F target genes and prexasertib sensitivity and identified innate immunity genes associated with prexasertib resistance. Functional RNAi studies supported a causal role of replication fork components as modulators of prexasertib response. Mechanisms that protect cells from oncogene-induced replication stress may safeguard tumors from such stress induced by a CHK1 inhibitor, resulting in acquired drug resistance. Furthermore, resistance to prexasertib may be shaped by innate immunity.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27400